Study Hypotheses:~Stereotactic Arrhythmia Radioablation (STAR) ablation is a safe and feasible option for cardiomyopathy patients for management of refractory ventricular tachycardia.~STAR can be performed with available cardiac imaging, prior mapping/electrogram information, and standard ECGs without a multi-electrode ECG vest.~Study Objectives:~Evaluate the safety of STAR in a local cohort~Estimate effectiveness of STAR in reducing VT burden~Study Design: Prospective single center, single arm, non-randomized trial.~Number of patients: 20 patients~Study Duration: Enrollment will occur over three years and at least minimum follow up of six months~Study Population: Adult patients with a cardiomyopathy and ventricular tachycardia who have failed conventional anti-arrhythmic management.~Primary safety endpoint: Any treatment-related serious adverse events in the first 90 days.~Primary efficacy endpoint: Reduction in VT episodes tracked by ICD with a six week blanking period.~Statistical methodology: Wilcoxon matched-pairs signed-ranks test to compare the number of treated episodes before and after.~Assessment of events: Adjudicated by study investigators~Economic Analysis: Costs and resources required for STAR .Compare costs between the patients undergoing STAR with conventional catheter-based VT ablation.
Stereotactic Arrhythmia Radioablation (STAR) ablation is a safe and feasible option for cardiomyopathy patients for management of refractory ventricular tachycardia.~STAR can be performed with available cardiac imaging, prior mapping/electrogram information, and standard ECGs without a multi-electrode ECG vest.